Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


Usefulness of Total PSA Value in Prostate Diseases Diagnosis.

Prcic A, Begic E, Hiros M.

Acta Inform Med. 2016 Jun;24(3):156-61. doi: 10.5455/aim.2016.24.156-161. Epub 2016 Jun 4.


Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.

Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, Roy R, Sachdev M, Loughlin KR, Moses MA.

BMC Cancer. 2015 Apr 11;15:259. doi: 10.1186/s12885-015-1284-z.


Screening for prostate cancer: the debate continues.

Matrana MR, Atkinson B.

J Adv Pract Oncol. 2013 Jan;4(1):16-21. Review.


Pairing physician education with patient activation to improve shared decisions in prostate cancer screening: a cluster randomized controlled trial.

Wilkes MS, Day FC, Srinivasan M, Griffin E, Tancredi DJ, Rainwater JA, Kravitz RL, Bell DS, Hoffman JR.

Ann Fam Med. 2013 Jul-Aug;11(4):324-34. doi: 10.1370/afm.1550.


Ultrasound elastography as a tool for imaging guidance during prostatectomy: initial experience.

Fleming IN, Kut C, Macura KJ, Su LM, Rivaz H, Schneider CM, Hamper U, Lotan T, Taylor R, Hager G, Boctor E.

Med Sci Monit. 2012 Nov;18(11):CR635-42.


Is a prostate cancer screening anxiety measure invariant across two different samples of age-appropriate men?

Linder SK, Swank PR, Vernon SW, Morgan RO, Mullen PD, Volk RJ.

BMC Med Inform Decis Mak. 2012 Jun 8;12:52. doi: 10.1186/1472-6947-12-52.


A community-driven intervention for prostate cancer screening in African Americans.

Patel K, Ukoli F, Liu J, Beech D, Beard K, Brown B, Sanderson M, Kenerson D, Cooper L, Canto M, Blot B, Hargreaves M.

Health Educ Behav. 2013 Feb;40(1):11-8. doi: 10.1177/1090198111431275. Epub 2012 Apr 16.


Novel diagnostic biomarkers for prostate cancer.

Madu CO, Lu Y.

J Cancer. 2010 Oct 6;1:150-77.


Sensitivity study and optimization of a 3D electric impedance tomography prostate probe.

Borsic A, Halter R, Wan Y, Hartov A, Paulsen KD.

Physiol Meas. 2009 Jun;30(6):S1-18. doi: 10.1088/0967-3334/30/6/S01. Epub 2009 Jun 2.


Community-based free prostate cancer screening program.

Jandorf L, Chang MS, Smith K, Florio A, Hall SJ.

Prog Community Health Partnersh. 2007 Fall;1(3):215-20.


Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study.

Guerra CE, Jacobs SE, Holmes JH, Shea JA.

J Gen Intern Med. 2007 Jul;22(7):901-7.


A test of knowledge about prostate cancer screening. Online pilot evaluation among Southern California Physicians.

Bell DS, Hays RD, Hoffman JR, Day FC, Higa JK, Wilkes MS.

J Gen Intern Med. 2006 Apr;21(4):310-4. Epub 2006 Feb 22.


Do men know that they have had a prostate-specific antigen test? Accuracy of self-reports of testing at 2 sites.

Chan EC, Vernon SW, Ahn C, Greisinger A.

Am J Public Health. 2004 Aug;94(8):1336-8.


Physician perspectives on the importance of facts men ought to know about prostate-specific antigen testing.

Chan EC, Vernon SW, Haynes MC, O'Donnell FT, Ahn C.

J Gen Intern Med. 2003 May;18(5):350-6.


Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message?

Chan EC, Vernon SW, O'Donnell FT, Ahn C, Greisinger A, Aga DW.

Am J Public Health. 2003 May;93(5):779-85.


Prostate cancer.

Mazhar D, Waxman J.

Postgrad Med J. 2002 Oct;78(924):590-5. Review.


The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L.

CMAJ. 2000 Apr 4;162(7):987-92.


The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L.

CMAJ. 2000 Apr 4;162(7):977-83.


Growth hormone and prostate cancer: guilty by association?

Grimberg A, Cohen P.

J Endocrinol Invest. 1999;22(5 Suppl):64-73. Review.

Items per page

Supplemental Content

Write to the Help Desk